Metabolife founder sentenced
This article was originally published in The Tan Sheet
Former Metabolife President Michael Ellis is sentenced to six months in prison and ordered to pay a $20,000 fine after pleading guilty to making false statements to federal regulators, according to a judgment filed June 10 in the U.S. District Court for the Southern District of California in San Diego. Ellis told FDA in 1998 that his company had never received any consumer complaints related to its ephedra-containing Metabolife 365. The weight-control supplement firm later released 13,000 patient complaints during a criminal investigation by the Department of Justice (1"The Tan Sheet" Aug. 19, 2002, p. 3)...
You may also be interested in...
Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records
An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma
The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.